Human Alpha-Aminoadipic Semialdehyde Synthase (AASS)

A Target Enabling Package (TEP)

<table>
<thead>
<tr>
<th>Gene ID / UniProt ID / EC</th>
<th>10157 / Q9UDR5 / 1.5.1.8, 1.5.1.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Nominator</td>
<td>Paulo Arruda (UNICAMP, Brazil)</td>
</tr>
<tr>
<td>SGC Authors</td>
<td>Jola Kopec, Izabella Pena, Elzbieta Rembeza, Mark McLaughlin, Oleg Fedorov, Claire Strain-Damerell, Solenne Goubin, Sabrina MacKinnon, Nicola Burgess-Brown, Paul Brennan, Alex MacKenzie, Paulo Arruda, Wyatt W. Yue</td>
</tr>
<tr>
<td>Collaborating Authors</td>
<td>N/A</td>
</tr>
<tr>
<td>Target PI</td>
<td>Wyatt Yue (SGC Oxford)</td>
</tr>
<tr>
<td>Therapeutic Area(s)</td>
<td>Metabolic &amp; Neurological disorders</td>
</tr>
<tr>
<td>Disease Relevance</td>
<td>Gene upstream of ALDH7A1, the molecular cause of pyridoxine-dependent epilepsy (OMIM 266100)</td>
</tr>
<tr>
<td>Date approved by TEP Evaluation Group</td>
<td>2nd June 2017</td>
</tr>
<tr>
<td>Document version</td>
<td>Version 7</td>
</tr>
<tr>
<td>Document version date</td>
<td>October 2020</td>
</tr>
<tr>
<td>Affiliations</td>
<td>N/A</td>
</tr>
</tbody>
</table>

We respectfully request that this document is cited using the DOI reference as given above if the content is used in your work.

**USEFUL LINKS**

(GeneCards, Open Targets, IMPC)

(Please note that the inclusion of links to external sites should not be taken as an endorsement of that site by the SGC in any way)

**SUMMARY OF PROJECT**

This work provides the early tools to develop substrate reduction inhibitors for a genetic childhood seizure disorder, with the hypothesis to target the enzyme (AASS) upstream of the defective gene (ALDH7A1) in the human lysine metabolic pathway. This TEP package includes recombinant human AASS purification protocols, structures of the AASS second domain in different states, *in vitro* assays to detect ligand binding (differential scanning fluorimetry) and enzyme activity (NADH formation) of human AASS, as well as initial chemical matters.

For more information regarding any aspect of TEPs and the TEP programme, please contact teps@thesgc.org
Genetic linkage – Pyridoxine-dependent epilepsy (PDE) is an autosomal recessive neonatal seizure disorder, caused by inherited mutations in the ALDH7A1 gene of the lysine metabolic pathway (1). To date, > 80 disease-causing alleles have been reported, half of which are missense changes on the encoded protein ALDH7A1 (aka antiquitin or α-aminoadipic semialdehyde dehydrogenase). A main pathogenic driver of PDE is accumulation of α-aminoadipate semialdehyde (AASA), substrate for ALDH7A1 (2), as well as its cyclic form L-Δ1-piperidine-6 carboxylate (P6C). The latter reacts with pyridoxal 5’-phosphate (PLP) thereby depleting its availability in the cell as cofactor for > 140 metabolic reactions.

Unmet need – The mainstay treatment for PDE is administration of pyridoxine, a precursor of PLP, which reduces epileptic episodes in a subset of patients. However, the delay in neurodevelopment and cognition, found in >75% of PDE patients, is not repaired by pyridoxine (3), underlying the need for alternative therapies.

Hypothesis – We propose that inhibiting the enzyme upstream of ALDH7A1, namely aminoadipate semialdehyde synthase (AASS), to reduce accumulation of AASA/P6C could serve as substrate reduction therapy for PDE (left).

The therapeutic rationale:
(a) The elevated plasma and urine levels of AASA/P6C in patient cells arise predominantly from the lysine degradation pathway containing the AASS enzyme step (and not the alternative pipecolate pathway) (4);
(b) A few reported individuals with inherited AASS mutations present a clinically benign metabolic condition (hyperlysinemia type I; (5)).

RESULTS – THE TEP
Human AASS (hAASS) is a bi-functional enzyme catalysing the first two steps in lysine catabolism (5), via its N-terminal lysine ketoglutarate reductase (LKR; EC 1.5.1.8) and C-terminal saccharopine dehydrogenase (SDH; EC 1.5.1.9) domains (below).

Proteins purified: hAASS LKR and SDH domains, and full-length protein
We have expressed and purified human hAASS-LKR (aa 23-452, in E. coli) and hAASS-SDH (aa 455-926, in insect Sf9) domains separately, and as near-full-length polypeptide (aa 23-926, in E. coli).

Structural data: hAASS-SDH domain in apo and NAD⁺-bound states
We determined the structures of hAASS-SDH in the apo state at 1.9 Å resolution and in binary complex with NAD⁺ at 2.7 Å resolution.

The hAASS-SDH protomer comprises three structural domains (above): domain I is a NAD⁺ binding Rossmann-like fold, domain II is an α/β fold responsible for substrate binding and dimerization (above, inset), and domain III is all-α domain regulating active site opening and closure.
In the binary complex, NAD$^+$ is bound in the Gly-rich motif of domain I. hAASS-SDH preferentially uses NAD$^+$ over NADP$^+$, because the anionic Asp512 and bulky Met513 side-chains preclude any possibility to accommodate a 2’ ribose phosphate in NADP$^+$.

The hAASS-SDH apo and binary structures superimpose with a relatively high Cα-rmsd (1.0 Å), suggesting cofactor-dependent conformational changes (left). We observed a 7° rigid-body rotation of domain III relative to the protein core, resulting in tightening of the active site.

**In vitro assays: differential scanning fluorimetry and fluorescence activity assay**

**Differential scanning fluorimetry** – We adopted DSF to detect binding of native ligands, showing that the cofactor NAD$^+$ alone, but not substrate saccharopine alone, causes a shift in melting temperature (ΔTm) of 2-4°C, while substrate and cofactor together lead to a total ΔTm of 6.5°C.

**Enzyme activity** – We measured hAASS-SDH activity by following the NAD$^+$ reduction to NADH with fluorescence when excited at 340 nm. We confirmed in vitro activity for purified hAASS-SDH, yielding KM values of 0.1 mM and 1.3 mM for NAD$^+$ and saccharopine respectively (right).

**Chemical starting points from crystal soaking studies**

A small fragment soaking campaign by crystallography has been performed. To date we have identified a proline ligand (Pro) in the active site of hAASS-SDH:
- bound in a pocket where the substrate saccharopine is expected to bind (left)
- key charge interaction between proline carboxylate and invariant Arg726 at the bottom of this pocket (below, left)
- solution data from DSF showed that Pro caused a ΔTm shift of 3°C to the protein

For more information regarding any aspect of TEPs and the TEP programme, please contact teps@thesgc.org
For more information regarding any aspect of TEPs and the TEP programme, please contact teps@thesgc.org

A number of commercially available proline analogues (2-6) has been acquired. From these, we have further determined the crystal structure bound with compound 2 within the same substrate pocket in the active site (above, right). Compound 2 retains a charge interaction with Arg726, but also picks up hydrogen bonds with the conserved residues Thr724 and Tyr648, as well as van der Waals interaction with Met870. Four other compounds (3-6) have shown inhibition of SDH activity at low mM concentrations, and will be subjected to chemistry optimization and soaking studies in future.

<table>
<thead>
<tr>
<th>Bound to substrate pocket</th>
<th>Inhibition of activity at low mM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, Proline 2.67 Å</td>
<td>Sigma 689017</td>
</tr>
<tr>
<td>2, 2.28 Å</td>
<td>Fluorochem 209339, Sigma I5109</td>
</tr>
<tr>
<td>3</td>
<td>Enamine 12587</td>
</tr>
<tr>
<td>4</td>
<td>CombiBlocks SS2281</td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

**IMPORTANT:** Please note that the existence of small molecules within this TEP indicates that chemical matter can bind to the protein in a functionally relevant pocket. As such these molecules should not be used as tools for functional studies of the protein unless otherwise stated as they are not sufficiently potent or well-characterised to be used in cellular studies. The small molecule ligands are intended to be used as the basis for future chemistry optimisation to increase potency and selectivity and yield a chemical probe or lead series.

**Ongoing translational work**

1. **HTS with activity assay** - Our fluorescence activity assay has been adopted and miniaturized by NIH-NCATS (Anton Simeonov). To date, they have carried out a pilot screen of 4625 compounds from their approved and investigational libraries (NPC, MIPE). Some hits with IC₅₀ <10 µM have been validated by counter-screens (NADH-Glo assay, HPGD activity assay), and are also replicated in our in-house activity assay. Expanded screening of the NPACT (n=10k) and Genesis (n=100k) libraries is currently underway.

2. **Chemistry optimisation Pro-based ligands** – Several series of compounds and analogues have been synthesised. Exploration of sulfonamide derivatives and substitution of the proline core are of priority, and a small library of synthesized compounds is being assessed by activity assay and structural studies (Mark McLaughlin, Manchester Metropolitan University).

3. **Testing in patient cells and disease models** – Lead compounds from activity and crystallography based screening will be tested for their efficacy in available patient skin fibroblasts (Philippa Mills, UC London) as well as a PDE model in zebrafish (Alex MacKenzie, CHEO Canada). Data from our collaborators have provided the cellular proof-of-concept for AASS inhibition: (i) shRNA knockdown of AASS in PDE fibroblasts significantly reduced levels of toxic metabolites and rescued disease phenotypes; (ii) AASS knock down in HEK293T cells did not confer detrimental phenotypes.

4. Our TEP reagents (recombinant AASS proteins) have enabled researchers from University of Colorado School of Medicine (van Hove, Coughlin, Wempe) in their discovery of a new metabolite biomarker resulting from the lysine degradation pathway, which accumulates in PDE patients. This work has now been published(7).

**Collaborations**

A special thanks to our collaborators Anton Simeonov (NIH-NCATS), Paul Brennan (SGC-ODDI), Mark McLaughlin (Manchester Metropolitan University), Philippa Mills (UC London), and Alex MacKenzie (CHEO Canada).

**CONCLUSION**

Despite the first report of the aminoadipate semialdehyde synthase (AASS) gene and enzyme in the 1980s (6), three decades on, there remains a distinct lack of biochemical and structural characterization that illuminates the enzymatic properties and mechanism. The AASS TEP project and outputs therefore aim to address this gap, and importantly provide a starting point for structure-based drug design. PDE is a debilitating rare disease with an unmet medical need. With the therapeutic proof-of-concept already in
place from our clinician collaborators, we aim to develop this into a translational drug discovery project as the next step, with collaborations in HT screening and validation in relevant cell lines and disease models.

**FUNDING INFORMATION**
The work at the SGC has been funded by a grant from the Wellcome [106169/ZZ14/2].

**ADDITIONAL INFORMATION**

<table>
<thead>
<tr>
<th>Structure Files</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PDB ID</strong></td>
</tr>
<tr>
<td>5O1P</td>
</tr>
<tr>
<td>5L78</td>
</tr>
<tr>
<td>5O1O</td>
</tr>
<tr>
<td>5O1N</td>
</tr>
</tbody>
</table>

**Materials and Methods**

**Protein expression, purification and assay procedures of hAASS-SDH**

Vector: pFB-LIC-Bse  
Cell line: DH10Bac  
Tags and additions: N-terminal, TEV protease cleavable hexahistidine tag

Construct protein sequence:

```
MGHHHHHHSSGLVQIVIGLTVNLAHLRRP*SMALPDKYKIIQITLRESRERAQSLSMGTRRKLVLGSGYIEPVLEYLSRDGIEITVGS
DMKNIQEQLGKYNINPVMIDICKQEKKGLFLVAQDKLLVISSLPPYVLHPVLVAKACITNKVNMVTASYITPALKLEKESVEDAGI
TIIGELGLDPGLDMLAMESIDKAVEGATIESYISYCGGLPAPHSNLPRLYKFSWSPGVMLNVMSATYLDGGKVNNVAG
GISFLDAPTSMDFPGLNLEGSFPRNDRKTYAIEYISAHLLRGLRTGLRKYKMALKALNFVKGKLGLINREALPAFRPANE
PLTWKQLCDLVGIPSSEDHVLKEAVKKGDDNTQLEAAEWEGLGLDEQVPQAESIDALSKLHVMKLSYGPEEKMIDVMRDSFGI
RHPSGHELHKTIDLVAAYGDINGFSAMAKTVGPTAMAAKMVLIDGEIGAKGLMGPSKEIYGPILERIKAEGIYTTQSTIKP
(underlined sequence contains vector encoded His-tag and TEV protease cleavage site*)
```

Bacmid DNA was prepared from DH10Bac cells and using to transfect Sf9 insect cells for the preparation of initial baculovirus. AASS protein was expressed from infected Sf9 cells cultivated in InsectXpress medium (Lonza) for 72 hours at 27°C.

Harvested cells were resuspended in lysis buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 5% Glycerol, 20 mM Imidazole pH 7.4, 0.5 mM TCEP, 1 µL per 1 mL protease inhibitor cocktail EDTA-free). Cell pellet was dissolved in approximately 200 mL lysis buffer and broken by homogenization by 2 passes at 12,000 psi. The cell debris was pelleted at 35000 x g, 1h and the supernatant used for purification on a gravity flow Ni-NTA column (5 mL). Buffers used are detailed hereafter;  
Binding Buffer: 50 mM HEPES pH 7.4, 500 mM NaCl, 5% Glycerol, 20 mM Imidazole pH 7.4, 0.5 mM TCEP  
Wash Buffer: 50 mM HEPES pH 7.4, 500 mM NaCl, 5% Glycerol, 40 mM Imidazole pH 7.4, 0.5 mM TCEP  
Elution Buffer: 50 mM HEPES pH 7.4, 500 mM NaCl, 5% Glycerol, 250 mM Imidazole pH 7.4, 0.5 mM TCEP

The clarified cell extract was added to 5 ml of Ni-NTA resin pre-equilibrated with lysis buffer and passed through a glass column. The column was then washed with Binding Buffer (2 x 50 mL) and Wash Buffer (2 x 50 mL). The protein was eluted with Elution Buffer in 5 x 5 mL fractions. The eluted fractions from column 1 were pooled and concentrated to 5 mL with a 30 kDa MWCO spin concentrator and injected into an S200 16/60
column (pre-equilibrated in GF Buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 0.5 mM TCEP, 5% Glycerol)) at 1.0 mL/min. 1.5 mL-fractions were collected. The eluted protein was cleaved overnight at 4 °C by TEV protease (1/20 (w/w)). The following day protein sample was loaded onto 0.5ml Ni-sepharose column pre-equilibrated with GF buffer to remove uncleaved protein. Pooled protein fractions were concentrated to 13 mg/mL using a 30 kDa mwco concentrator.

Activity assay and screening

The SDH activity of hAASS was measured by following NAD+ reduction to NADH, taking advantage that the reduced form of NADH is fluorescent when excited with 340 nm light. We adopted the assay into 384-well format, with detection using the PheraStar fluorescence reader (BMG Labtech) (Excitation/Emission = 340/480 nm). This assay gave a linear response with protein concentration up to 150 nM. A typical reaction consists of 100 nM purified enzyme, 0.2 mM NAD+, 1.3 mM saccharopine. The reaction buffer consists of 25 mM HEPES pH 7.4, 100 mM NaCl, 0.1% BSA, 0.05% CHAPS. The compound libraries (LOPAC (Sigma) and NIH Clinical Collections I&II) were screened in-house at 20 μM compound concentration.

Differential scanning fluorimetry

DSF was performed in a 96-well plate using an Mx3005p RT-PCR machine (Stratagene) with excitation and emission filters of 492 and 610 nm, respectively. Each well consisted of 2 µL protein in 2 µM DSF buffer (150 mM NaCl, 10 mM HEPES pH 7.5), 2 µL SYPRO ORANGE diluted 1000-fold in DSF buffer from the manufacturers stock (Invitrogen), and (if applicable) 2 µL ligand at various concentrations. Fluorescence intensities were measured from 25 to 96°C with a ramp rate of 3°C/min.

Crystallization

Apo crystals were prepared by mixing 50 nL of hAASS-SDH protein (80 mg/mL) with 100 nL of reservoir solution containing 20% PEG3350, 0.1M Tris pH 7.5 and 0.2-0.33 M sodium malonate. NAD+ -bound crystals were prepared by mixing 100 nL of hAASS-SDH (18 mg/mL, in molar excess of NAD+) with 50 nL of reservoir solution containing 25% PEG3350, 0.2M NaCl and 0.1M tris pH 8.5. Crystals were cryo-protected in 9% butanediol before freezing in liquid nitrogen. For the fragment screening campaign, crystals were soaked with compounds (10/50/500 mM) in the crystallization solution supplemented with 8% butanediol for 5-30 min, and frozen in liquid nitrogen.

Structure determination procedures

hAASS-SDH apo and NAD+ -bound crystals belong to different spacegroups (P43212 vs P212121). The structure of hAASS-SDH was solved by molecular replacement with the program PHASER, using the fungal saccharopine reductase from S.cerevisiae (PDB code 2AXQ) as search model (38% sequence identity). Two molecules were found in the asymmetric unit (a.u.). The initial model was rebuilt using phenix.autobuild. A bound NAD+ molecule in the active site was identified by difference Fourier method and manually placed into the electron density using Coot. To complete the model iterative cycles of phenix.refine including TLS refinement followed by manual model building for missing residues using coot were performed. No NCS restraints were applied due to conformational differences in domain III (res 278-376) of the two copies in the a.u. Solvent atoms were placed during the last four rounds of refinement using phenix.refine. For the fragment screening campaign, ligands were identified by DIMPLE (https://github.com/ccp4/dimple) using difference density maps. Weaker binders with low occupancy were evaluated using PANDDA (https://pandda.bitbucket.io/), based on statistical models to find ligand density present in a given dataset that is not present in majority of datasets. Coordinates and structure factors for all data sets are deposited in the RCSB Protein Data Bank. Data collection and refinement statistics are available from the PDB pages.

Commercially available reagents

For more information regarding any aspect of TEPs and the TEP programme, please contact teps@thesgc.org
CRISPR/Cas9 knockout plasmids
SCBT: Cat # sc-406408
Genscript: Cat # 10157

References


We respectfully request that this document is cited using the DOI value as given above if the content is used in your work.